Company Overview

Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people's lives. Our Surgical and Vision Care products touch the lives of people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases, and refractive errors.

The company was founded by Mr. Robert Alexander and Mr. William Conner in 1945 and is headquartered in Geneva, Switzerland. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals, and programs that advance access to quality eye care.

Market Position & Financials

Alcon (ALC) holds a significant position as the global leader in eye care. As of July 2025, the company's market capitalization is approximately $43.1 billion. Alcon's 52-week performance shows a high of $101.10 and a low of $80.48.

Recent Financial Performance

- Q2 2025 Results:

- Alcon reported Q2 net sales of $2.58 billion, a 3.8% year-over-year increase.

- Alcon reported Q2 core earnings of $0.76 per diluted share, up from $0.74 a year earlier.

- Alcon's Q2 free cash flow of $681 million for the first half of 2025 underscores its financial flexibility.

- Full Year 2024 Performance:

- Full-year 2024 sales were $9.8 billion, up 5% on a reported basis, or up 6% on a constant currency basis.

- Full-year 2024 diluted EPS was $2.05 (up 5% reported, 11% constant currency); core diluted EPS was $3.05 (up 11% reported, 16% constant currency).

- The company generated record $2.1 billion of cash from operations in the full year.

Business Segments

Alcon operates through two primary segments: Surgical and Vision Care.

Surgical Segment

The Surgical segment offers a comprehensive range of products for surgical procedures. This includes:

- Equipment, instrumentation, and diagnostics.

- Intraocular lenses (IOLs) and other implantables.

- Consumables, such as viscoelastics, surgical solutions, incisional instruments, and surgical custom packs.

These products are used in procedures like cataract, vitreoretinal, refractive laser, and glaucoma surgery.

Key surgical products include:

- Centurion vision system, LenSx laser system, Verion reference unit and Verion digital marker, ARGOS biometer, SMARTCATARACT health platform, NGENUITY 3D visualization system, LuxOR surgical ophthalmic microscope, and ORA system for intra-operative measurements.

- Monofocal, Toric, and Presbyopia-Correcting IOLs, along with delivery systems like AutonoMe and UltraSert.

Vision Care Segment

The Vision Care segment focuses on contact lenses and ocular health products. This segment comprises:

- Daily disposable, reusable, and color-enhancing contact lenses.

- A portfolio of ocular health products, including over-the-counter items for dry eye, contact lens care, and ocular allergies.

- Ocular vitamins and redness relievers.

Innovation & Recent Developments

Product Launches

Alcon has continuously introduced innovative products to the market, including:

- Unity VCS (Vitreoretinal Cataract System) and Unity CS (Cataract System).

- PanOptix Pro, Voyager, Precision7, and Systane Pro PF.

The UNITY® Vitreoretinal Cataract System (VCS) and UNITY® Cataract System (CS) represent breakthrough technologies for eye surgery, combining vitreoretinal and cataract surgical capabilities in one integrated platform. These systems offer significant improvements over Alcon's previous CONSTELLATION® and CENTURION® systems, featuring up to 2x faster nucleus removal with 40% less energy, and the world's fastest vitrectomy probe at 30,000 cuts per minute.

Strategic Acquisitions

Alcon (NYSE: ALC) has actively pursued strategic acquisitions to enhance its portfolio:

- Announced a definitive merger agreement to acquire LENSAR (NASDAQ: LNSR) in a deal worth up to $430 million.

- Announced its intention to acquire LumiThera, Inc., and its photobiomodulation (PBM) device for treating early and intermediate dry Age-Related Macular Degeneration (AMD).

Shareholder Returns

Alcon distributes dividends to its shareholders.

- The last reported dividend per share was 0.33 USD.

- As of today, the Trailing Twelve Months (TTM) Dividend Yield is 0.44%.

- Shareholders approved a dividend of CHF 0.28 per share at the 2025 Annual General Meeting.

2025 Outlook

Alcon has provided its outlook for 2025, with updated guidance reflecting market conditions.

- The company expects net sales to be between $10.4 billion and $10.5 billion.

- Core diluted EPS is projected to be between $3.05 and $3.15.

- Alcon revised its full-year 2025 guidance to 4-5% revenue growth (previously 6-7%) and a core operating margin of 19.5-20.5%.

Alcon continues to position itself as a leader in the expanding eye care market, leveraging its comprehensive product portfolio, global reach, and commitment to innovation to address the growing needs of an aging population worldwide.